Document is current
Any future updates will be listed below
-
Authors
Campanella, Gabriele https://orcid.org/0000-0001-6299-1311
Chen, Shengjia https://orcid.org/0000-0003-1556-0679
Singh, Manbir
Verma, Ruchika
Muehlstedt, Silke
Zeng, Jennifer
Stock, Aryeh https://orcid.org/0000-0003-1500-5819
Croken, Matt
Veremis, Brandon
Elmas, Abdulkadir https://orcid.org/0000-0002-7999-5770
Shujski, Ivan
Neittaanmäki, Noora
Huang, Kuan-lin https://orcid.org/0000-0002-5537-5817
Kwan, Ricky
Houldsworth, Jane https://orcid.org/0000-0002-6781-1700
Schoenfeld, Adam J. https://orcid.org/0000-0002-2644-1416
Vanderbilt, Chad https://orcid.org/0000-0002-8114-0237
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (LM013766)
Grant from the Warren Alpert Foundation through the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 2 April 2025
First Online: 17 April 2025
Competing interests
: C.V. reports intellectual property rights and equity interest in Paige.AI, Inc. A.J.S. reports consulting/advising role to J&J, Bayer, KSQ therapeutics, BMS, Merck, Astrazeneca, Synthekine, cTRL therapeutics, Regeneron, Enara Bio, Perceptive Advisors, Oppenheimer and Co, Umoja Biopharma, Legend Biotech, Iovance Biotherapeutics, Obsidian Therapeutics, Prelude Therapeutics, Immunocore, Lyell Immunopharma, Amgen and Heat Biologics. A.J.S. receives research funding from GSK (Inst), Obsidian (Inst), Lilly (Inst), PACT pharma (Inst), Iovance Biotherapeutics (Inst), Achilles therapeutics (Inst), Merck (Inst), Synthekine (Inst), BMS (Inst), Harpoon Therapeutics (Inst), AffiniT therapeutics (Inst), Legend Therapeutics (Inst), Synthekine (Inst) and Amgen (Inst). G.C., S.C., M.S., R.V., S.M., J.Z., A.S., M.C., B.V., A.E., I.S., N.N., K.H., R.K., J.H. declare no competing interests.
